Cargando…
Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers have been investigated to predict outcomes in pati...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699991/ https://www.ncbi.nlm.nih.gov/pubmed/34943412 http://dx.doi.org/10.3390/diagnostics11122170 |
_version_ | 1784620648056750080 |
---|---|
author | Takeda, Takayuki Yamada, Tadaaki Tanimura, Keiko Nakano, Takayuki Ishida, Masaki Tachibana, Yusuke Shiotsu, Shinsuke Horiuchi, Shigeto Hibino, Makoto Okada, Asuka Chihara, Yusuke Takayama, Koichi |
author_facet | Takeda, Takayuki Yamada, Tadaaki Tanimura, Keiko Nakano, Takayuki Ishida, Masaki Tachibana, Yusuke Shiotsu, Shinsuke Horiuchi, Shigeto Hibino, Makoto Okada, Asuka Chihara, Yusuke Takayama, Koichi |
author_sort | Takeda, Takayuki |
collection | PubMed |
description | The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers have been investigated to predict outcomes in patients with several cancers, their usefulness in targeted therapies is scarce, and their significance has never been reported in patients receiving first-line treatment with alectinib. Meanwhile, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) has been investigated during crizotinib treatment. This multicenter retrospective study evaluated 42 consecutive Japanese patients with ALK-positive NSCLC who received first-line treatment with alectinib. Immunological and nutritional markers were evaluated at baseline and 3 weeks after alectinib introduction, and their significance in predicting progression-free survival (PFS) was explored. PFS duration was significantly associated with baseline PLR (hazard ratio (HR): 2.49, p = 0.0473), systemic immune-inflammation index (SII; HR: 2.65, p = 0.0337), prognostic nutrition index (PNI; HR: 4.15, p = 0.00185), and the 3-week values for SII (HR: 2.85, p = 0.0473) and PNI (HR: 3.04, p = 0.0125). Immunological and nutritional markers could be useful in predicting the outcomes of first-line treatment with alectinib. Since PLR and SII consist of platelet counts, platelet count could be an important constituent of these markers. |
format | Online Article Text |
id | pubmed-8699991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86999912021-12-24 Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib Takeda, Takayuki Yamada, Tadaaki Tanimura, Keiko Nakano, Takayuki Ishida, Masaki Tachibana, Yusuke Shiotsu, Shinsuke Horiuchi, Shigeto Hibino, Makoto Okada, Asuka Chihara, Yusuke Takayama, Koichi Diagnostics (Basel) Article The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers have been investigated to predict outcomes in patients with several cancers, their usefulness in targeted therapies is scarce, and their significance has never been reported in patients receiving first-line treatment with alectinib. Meanwhile, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) has been investigated during crizotinib treatment. This multicenter retrospective study evaluated 42 consecutive Japanese patients with ALK-positive NSCLC who received first-line treatment with alectinib. Immunological and nutritional markers were evaluated at baseline and 3 weeks after alectinib introduction, and their significance in predicting progression-free survival (PFS) was explored. PFS duration was significantly associated with baseline PLR (hazard ratio (HR): 2.49, p = 0.0473), systemic immune-inflammation index (SII; HR: 2.65, p = 0.0337), prognostic nutrition index (PNI; HR: 4.15, p = 0.00185), and the 3-week values for SII (HR: 2.85, p = 0.0473) and PNI (HR: 3.04, p = 0.0125). Immunological and nutritional markers could be useful in predicting the outcomes of first-line treatment with alectinib. Since PLR and SII consist of platelet counts, platelet count could be an important constituent of these markers. MDPI 2021-11-23 /pmc/articles/PMC8699991/ /pubmed/34943412 http://dx.doi.org/10.3390/diagnostics11122170 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Takeda, Takayuki Yamada, Tadaaki Tanimura, Keiko Nakano, Takayuki Ishida, Masaki Tachibana, Yusuke Shiotsu, Shinsuke Horiuchi, Shigeto Hibino, Makoto Okada, Asuka Chihara, Yusuke Takayama, Koichi Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib |
title | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib |
title_full | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib |
title_fullStr | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib |
title_full_unstemmed | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib |
title_short | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib |
title_sort | prognostic markers of survival among japanese patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving first-line alectinib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699991/ https://www.ncbi.nlm.nih.gov/pubmed/34943412 http://dx.doi.org/10.3390/diagnostics11122170 |
work_keys_str_mv | AT takedatakayuki prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT yamadatadaaki prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT tanimurakeiko prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT nakanotakayuki prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT ishidamasaki prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT tachibanayusuke prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT shiotsushinsuke prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT horiuchishigeto prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT hibinomakoto prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT okadaasuka prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT chiharayusuke prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib AT takayamakoichi prognosticmarkersofsurvivalamongjapanesepatientswithanaplasticlymphomakinasepositivenonsmallcelllungcancerreceivingfirstlinealectinib |